Regulatory Issues and Economic Efficiency

Journal of Rheumatology

Volumn 30, Issue SUPPL. 68, 2003, Pages 5-7

  Suarez Almazor, Maria E ^a   Drummond, Michael ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DRUG INDUSTRY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROGRAM; MANAGED CARE; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 0346749414     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1997.
2. Levine M, Taylor R, Ryan M, Sculpher M. Decision-making by healthcare payers. Respiratory Medicine 2002;96 Suppl C:S31-S38.
3. Drummond M. The relevance of health economic evaluation to health care decision makers. Spectrum Report. Waltham: Decision Resources Inc.; 2002.
4. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value in Health 2001;4:225-50.
5. PausJenssen AM, Singer PA, Detsky AS. Ontario's formulary committee: How recommendations are made. Pharmacoeconomics 2003;21:285-94.
6. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics 2000;18:55-62.
7. Ikegami N, Drummond M, Fukuhara S, Nishimura S, Torrance GW, Schubert F. Why has the use of health economic evaluation in Japan lagged behind that in other developed countries? Pharmacoeconomics 2002;20 Suppl 2:1-7.
8. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. London: National Institute for Clinical Excellence; 2000.